A review on schizophrenia and relapse - A quest for user-friendly psychopharmacotherapy

Human Psychopharmacology

Volumn 29, Issue 5, 2014, Pages 414-426

  Suzuki, Takefumi ^a,b   Uchida, Hiroyuki ^a,c   Takeuchi, Hiroyoshi ^a,c   Tsuboi, Takashi ^a   Hirano, Jinichi ^a   Mimura, Masaru ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Inokashira Hospital   (Japan)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

Antipsychotics; Prevention; Relapse; Review; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

ADVERSE DRUG REACTION; DRUG CHOICE; HUMAN; MAINTENANCE DRUG DOSE; META ANALYSIS; NEUROTOXICITY; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; RISK FACTOR; SCHIZOPHRENIA; META ANALYSIS (TOPIC); RECURRENT DISEASE;

ANTIPSYCHOTIC AGENTS; HUMANS; META-ANALYSIS AS TOPIC; RECURRENCE; RISK FACTORS; SCHIZOPHRENIA;

EID: 84922663829     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2421     Document Type: Review

References (171)

1. Addington J, Cornblatt BA, Cadenhead KS, et al. 2011. At clinical high risk for psychosis: outcome for nonconverters. Am J Psychiatry 168: 800-805. doi: 10.1176/appi.ajp.2011.10081191
2. Agid O, Foussias G, Remington G. 2010. Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention. Expert Opin Pharmacother 11: 2301-2317. doi: 10.1517/14656566.2010.499125
3. Aguglia E, Pascolo-Fabrici E, Bertossi F, Bassi M. 2007. Psychoeducational intervention and prevention of relapse among schizophrenic disorders in the Italian community psychiatric network. Clin Pract Epidemiol Ment Health 3: 7.
4. Altamura AC, Tacchini GL, Maes M. 1995. Haloperidol plasma 'threshold' levels for relapse prevention in schizophrenia: a study with haloperidol decanoate. Eur Neuropsychopharmacol 5 Suppl: 55-58.
5. Alvarez-Jimenez M, Priede A, Hetrick SE, et al. 2012. Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies. Schizophr Res 139: 116-128. doi: 10.1016/j.schres.2012.05.007
6. Andreasen NC, Liu D, Ziebell S, Vora A, Ho BC. 2013. Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. Am J Psychiatry 170: 609-615. doi: 10.1176/appi.ajp.2013.12050674
7. Ascher-Svanum H, Zhu B, Faries DE, et al. 2010. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry 10: 2. doi: 10.1186/1471-244X-10-2
8. Baghai TC, Möller HJ. 2008. Electroconvulsive therapy and its different indications. Dialogues Clin Neurosci 10: 105-117.
9. Baldessarini RJ, Cohen BM, Teicher MH. 1988. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 45: 79-91.
10. Barnes TR. 2004. Pharmacological strategies for relapse prevention in schizophrenia. Psychiatry 3: 37-40.
11. Barnes TRE, Drake R. 2007. Pharmacological strategies for relapse prevention in schizophrenia. Psychiatry 6: 351-356.
12. Barnes TR, Schizophrenia Consensus Group of British Association for Psychopharmacology. 2011. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 25: 567-620. doi: 10.1177/0269881110391123
13. Bonham C, Abbott C. 2008. Are second generation antipsychotics a distinct class? J Psychiatr Pract 14: 225-231. doi: 10.1097/01.pra.0000327312.04153.da
14. Bosveld-van Haandel LJ, Slooff CJ, van den Bosch RJ. 2001. Reasoning about the optimal duration of prophylactic antipsychotic medication in schizophrenia: evidence and arguments. Acta Psychiatr Scand 103: 335-346.
15. Bradford DW, Perkins DO, Lieberman JA. 2003. Pharmacological management of first-episode schizophrenia and related nonaffective psychoses. Drugs 63: 2265-2283.
16. Buchanan RW, Kreyenbuhl J, Kelly DL, et al. 2010. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 36: 71-93. doi: 10.1093/schbul/sbp116
17. Bushe CJ, Taylor M, Haukka J. 2010. Mortality in schizophrenia: a measurable clinical endpoint. J Psychopharmacol 24(4 Suppl): 17-25. doi: 10.1177/1359786810382468
18. Caseiro O, Pérez-Iglesias R, Mata I, et al. 2012. Predicting relapse after a first episode of non-affective psychosis: a three-year follow-up study. J Psychiatr Res 46: 1099-1105. doi: 10.1016/j.jpsychires.2012.05.001
19. Castro AP, Elkis H. 2007. Rehospitalization rates of patients with schizophrenia discharged on haloperidol, risperidone or clozapine. Rev Bras Psiquiatr 29: 207-212.
20. Chabannes JP, Bazin N, Leguay D, et al. 2008. Two-year study of relapse prevention by a new education program in schizophrenic patients treated with the same antipsychotic drug. Eur Psychiatry 23: 8-13.
21. Chen EY, Hui CL, Lam MM, et al. 2010. Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial. BMJ 341: c4024. doi: 10.1136/bmj.c4024
22. Chengappa KN, Parepally H, Brar JS, Mullen J, Shilling A, Goldstein JM. 2003. A random-assignment, double-blind, clinical trial of once- vs twice-daily administration of quetiapine fumarate in patients with schizophrenia or schizoaffective disorder: a pilot study. Can J Psychiatry 48: 187-194.
23. Ciompi L. 1980. Catamnestic long-term study on the course of life and aging of schizophrenics. Schizophr Bull 6: 606-618.
24. Ciudad A, San L, Bernardo M, et al. 2012. Relapse and therapeutic interventions in a 1-year observational cohort study of nonadherent outpatients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 36: 245-250. doi: 10.1016/j.pnpbp.2011.10.014
25. Csernansky JG, Schuchart EK. 2002. Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs 16: 473-484.
26. Csernansky JG, Mahmoud R, Brenner R, Risperidone-USA-79 Study Group. 2002. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 346: 16-22.
27. Cunningham Owens DG, Carroll A, Fattah S, Clyde Z, Coffey I, Johnstone EC. 2001. A randomized, controlled trial of a brief interventional package for schizophrenic out-patients. Acta Psychiatr Scand 103: 362-369.
28. Davis JM, Chen N. 2004. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol 24: 192-208.
29. De Hert M, Correll CU, Cohen D. 2010. Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study. Schizophr Res 117: 68-74. doi: 10.1016/j.schres.2009.12.029
30. Dell'Osso B, Glick ID, Baldwin DS, Altamura AC. 2013. Can long-term outcomes be improved by shortening the duration of untreated illness in psychiatric disorders? A conceptual framework. Psychopathology 46: 14-21. doi: 10.1159/000338608
31. Dencker SJ. 1981. The need for long-term neuroleptic treatment in schizophrenia. Acta Psychiatr Scand Suppl 291: 29-43.
32. Dingemans PMAJ, Lenior ME, Linszen DH. 1998. Personality and schizophrenic relapse. Int Clin Psychopharmacol 13(suppl 1): s89-95.
33. Eberhard J, Riley F, Levander S. 2003. Premorbid IQ and schizophrenia. Increasing cognitive reduction by episodes. Eur Arch Psychiatry Clin Neurosci 253: 84-88.
34. Eisner E, Drake R, Barrowclough C. 2013. Assessing early signs of relapse in psychosis: review and future directions. Clin Psychol Rev 33: 637-53. doi: 10.1016/j.cpr.2013.04.001
35. Eklund K, Forsman A. 1991. Minimal effective dose and relapse - double-blind trial: haloperidol decanoate vs. placebo. Clin Neuropharmacol 14 (Suppl 2): S7-12; discussion S12-15.
36. Emsley R, Fleischhacker WW. 2013. Is the ongoing use of placebo in relapse-prevention clinical trials in schizophrenia justified? Schizophr Res 150: 427-433. doi: 10.1016/j.schres.2013.09.008
37. Emsley R, Oosthuizen PP, Koen L, Niehaus DJ, Martinez G. 2012a. Symptom recurrence following intermittent treatment in first-episode schizophrenia successfully treated for 2 years: a 3-year open-label clinical study. J Clin Psychiatry 73(4): e541-7. doi: 10.4088/JCP.11m07138
38. Emsley R, Nuamah I, Hough D, Gopal S. 2012b. Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia. Schizophr Res 138: 29-34. doi: 10.1016/j.schres.2012.02.030
39. Emsley R, Chiliza B, Asmal L, Harvey BH. 2013. The nature of relapse in schizophrenia. BMC Psychiatry 13: 50. doi: 10.1186/1471-244X-13-50
40. Fialko L, Freeman D, Bebbington PE, et al. 2006. Understanding suicidal ideation in psychosis: findings from the Psychological Prevention of Relapse in Psychosis (PRP) trial. Acta Psychiatr Scand 114: 177-186.
41. Fusar-Poli P, Kempton MJ, Rosenheck RA. 2013. Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials. Int Clin Psychopharmacol 28: 57-66. doi: 10.1097/YIC.0b013e32835b091f
42. Gaebel W. 1995. Is intermittent, early intervention medication an alternative for neuroleptic maintenance treatment? Int Clin Psychopharmacol 9(Suppl 5): 11-16.
43. Gaebel W. 1997. Towards the improvement of compliance: The significance of psycho-education and new antipsychotic drugs. Int Clin Psychopharmacol 12(suppl 1): s37-42.
44. Gaebel W, Riesbeck M. 2013. Are there clinically useful predictors and early warning signs for pending relapse? Schizophr Res. pii: S0920-9964(13)00438-6. doi: 10.1016/j.schres.2013.08.003. [Epub ahead of print]
45. Gaertner I, Gaertner HJ, Vonthein R, Dietz K. 2001. Therapeutic drug monitoring of clozapine in relapse prevention: a five-year prospective study. J Clin Psychopharmacol 21: 305-310.
46. Gleeson JF, Rawlings D, Jackson HJ, McGorry PD. 2005. Early warning signs of relapse following a first episode of psychosis. Schizophr Res 80: 107-111.
47. Gleeson JF, Alvarez-Jimenez M, Cotton SM, Parker AG, Hetrick S. 2010. A systematic review of relapse measurement in randomized controlled trials of relapse prevention in first-episode psychosis. Schizophr Res 119: 79-88. doi: 10.1016/j.schres.2010.02.1073
48. Goghari VM, Harrow M, Grossman LS, Rosen C. 2013. A 20-year multi-follow-up of hallucinations in schizophrenia, other psychotic, and mood disorders. Psychol Med 43: 1151-1160. doi: 10.1017/S0033291712002206
49. Goldstein MJ. 1994. Psychoeducational and family therapy in relapse prevention. Acta Psychiatr Scand Suppl 382: 54-57.
50. Goldstein G, Shemansky WJ. 2000. Length and number of hospitalizations in two cohorts of veterans with chronic schizophrenia. Psychiatr Serv 51: 245-247.
51. Gopal S, Berwaerts J, Nuamah I, et al. 2011. Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia. Neuropsychiatr Dis Treat 7: 93-101. doi: 10.2147/NDT.S17177
52. Haddad PM, Sharma SG. 2007. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 21: 911-936.
53. Haijma SV, Van Haren N, Cahn W, et al. 2013. Brain volumes in schizophrenia: a meta-analysis in over 18 000 subjects. Schizophr Bull 39: 1129-1138. doi: 10.1093/schbul/sbs118
54. Hamann J, Mendel R, Heres S, Leucht S, Kissling W. 2010. How much more effective do depot antipsychotics have to be compared to oral antipsychotics before they are prescribed? Eur Neuropsychopharmacol 20: 276-279. doi: 10.1016/j.euroneuro.2010.01.001
55. van Haren NE, Hulshoff Pol HE, Schnack HG, et al. 2007. Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study. Neuropsychopharmacology 32: 2057-2066.
56. van Haren NE, Hulshoff Pol HE, Schnack HG, et al. 2008. Progressive brain volume loss in schizophrenia over the course of the illness: evidence of maturational abnormalities in early adulthood. Biol Psychiatry 63: 106-113.
57. van Meijel B, Kruitwagen C, van der Gaag M, Kahn RS, Grypdonck MH. 2006. An intervention study to prevent relapse in patients with schizophrenia. J Nurs Scholarsh 38: 42-49.
58. Harrow M, Jobe TH, Faull RN. 2012. Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-yearlongitudinal study. Psychol Med 42: 2145-2155. doi: 10.1017/S0033291712000220
59. Harvey PD, Loewenstein DA, Czaja SJ. 2013. Hospitalization and psychosis: influences on the course of cognition and everyday functioning in people with schizophrenia. Neurobiol Dis 53: 18-25. doi: 10.1016/j.nbd.2012.10.022
60. Heller RF, Gemmell I, Patterson L. 2006. Helping to prioritise interventions for depression and schizophrenia: use of Population Impact Measures. Clin Pract Epidemiol Ment Health 2: 3.
61. Herz MI, Lamberti JS. 1995. Prodromal symptoms and relapse prevention in schizophrenia. Schizophr Bull 21: 541-551.
62. Hogarty GE. 1993. Prevention of relapse in chronic schizophrenic patients. J Clin Psychiatry 54 Suppl: 18-23.
63. Hong J, Windmeijer F, Novick D, Haro JM, Brown J. 2009. The cost of relapse in patients with schizophrenia in the European SOHO (Schizophrenia Outpatient Health Outcomes) study. Prog Neuropsychopharmacol Biol Psychiatry 33: 835-841. doi: 10.1016/j.pnpbp.2009.03.034
64. Howes OD, Egerton A, Allan V, McGuire P, Stokes P, Kapur S. 2009. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Curr Pharm Des 15: 2550-2559.
65. Hui CL, Tang JY, Leung CM, et al. 2013a.A3-year retrospective cohort study of predictors of relapse in first-episode psychosis in Hong Kong. Aust N Z J Psychiatry 2013a; 47: 746-753. doi: 10.1177/0004867413487229
66. Hui CL, Wong GH, Tang JY, et al. 2013b. Predicting 1-year risk for relapse in patients who have discontinued or continued quetiapine after remission from first-episode psychosis. Schizophr Res 150: 297-302. doi: 10.1016/j.schres.2013.08.010
67. Ikai S, Remington G, Suzuki T, et al. 2012. A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia. J Clin Psychiatry 73: 1147-1152. doi: 10.4088/JCP.12m07638
68. Johnstone EC, Geddes J. 1994. How high is the relapse rate in schizophrenia? Acta Psychiatr Scand Suppl 382: 6-10.
69. Ju PC, Chou FH, Lai TJ, et al. 2014. Long-acting injectables and risk for rehospitalization among patients with schizophrenia in the home care program in Taiwan. J Clin Psychopharmacol 34: 23-29. doi: 10.1097/JCP.0b013e3182a6a142
70. Kanahara N, Yoshida T, Oda Y, et al. 2013. Onset Pattern and Long-Term Prognosis in Schizophrenia: 10-Year Longitudinal Follow-Up Study. PLoS One 8(6): e67273. Print 2013.
71. Kane JM. 1995. Dosing issues and depot medication in the maintenance treatment of schizophrenia. Int Clin Psychopharmacol 10(Suppl 3): 65-71.
72. Kane JM. 1997. What can we achieve by implementing a compliance-improvement program? Int Clin Psychopharmacol 12(suppl 1): s43-46.
73. Kane JM. 2003. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. J Clin Psychiatry 64(Suppl 16): 34-40.
74. Kazadi, NJB, Moosa MYH, Jeenah FY. 2008. Factors associated with relapse in schizophrenia. S Afr J Psychiatry 14: 52-62.
75. Killackey E, Yung AR. 2007. Effectiveness of early intervention in psychosis. Curr Opin Psychiatry 20: 121-125.
76. Kim B, Lee S-H, Tae KC, et al. 2008. Effectiveness of a combined therapy of long-acting injectable risperidone and psychosocial intervention for relapse prevention in patients with schizophrenia. Clin Psychopharmacol Neurosci 6: 31-37.
77. Kishimoto T, Agarwal V, Kishi T, Leucht S, Kane JM, Correll CU. 2013a. Relapse prevention in schizophrenia: a systematic review and metaanalysis of second-generation antipsychotics versus first-generation antipsychotics. Mol Psychiatry 18: 53-66. doi: 10.1038/mp.2011.143
78. Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU. 2013b. Longacting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry 74: 957-965. doi: 10.4088/JCP.13r08440
79. Kishimoto T, Robenzadeh A, Leucht C, et al. 2014. Long-Acting Injectable vs Oral Antipsychotics for Relapse Prevention in Schizophrenia: A Meta-Analysis of Randomized Trials. Schizophr Bull 40: 192-213. doi: 10.1093/schbul/sbs150
80. Kissling W. 1994. Compliance, quality assurance and standards for relapse prevention in schizophrenia. Acta Psychiatr Scand Suppl 382: 16-24.
81. Klingberg S, Wittorf A, Fischer A, Jakob-Deters K, Buchkremer G, Wiedemann G. 2010. Evaluation of a cognitive behaviourally oriented service for relapse prevention in schizophrenia. Acta Psychiatr Scand 121: 340-350. doi: 10.1111/j.1600-0447.2009.01479.x
82. Knapp M, Locklear J, Järbrink K. 2009. Impact of psychotic relapse definitions in assessing drug efficacy and costs: comparison of quetiapine XR, olanzapine and paliperidone ER. Curr Med Res Opin 25: 1593-1603. doi: 10.1185/03007990903010623
83. Komatsu H, Sekine Y, Okamura N, et al. 2013. Effectiveness of Information Technology Aided Relapse Prevention Programme in Schizophrenia excluding the effect of user adherence: A randomized controlled trial. Schizophr Res 150: 240-244. doi: 10.1016/j.schres.2013.08.007
84. Lader M. 1998. Pharmacological prevention of relapse. Kaohsiung J Med Sci 14: 448-457.
85. Lafeuille MH, Gravel J, Lefebvre P, et al. 2013. Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics. J Med Econ 16: 1290-1299. doi: 10.3111/13696998.2013.841705
86. Leff JP. 1981. Prevention of relapse of schizophrenia by social and pharmacological treatments. Bibl Psychiatr 160: 15-21.
87. Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. 2003. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 160: 1209-1222.
88. Leucht S, Kissling W, Davis JM. 2009. Second-generation antipsychotics for schizophrenia: can we resolve the conflict? Psychol Med 39: 1591-1602. doi: 10.1017/S0033291709005455
89. Leucht S, Tardy M, Komossa K, et al. 2012. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 379(9831): 2063-2071. doi: 10.1016/S0140-6736(12)60239-6
90. Leucht S, Cipriani A, Spineli L, et al. 2013. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382(9896): 951-962. doi: 10.1016/S0140-6736(13)60733-3
91. Lewander T. 1996. Long-term studies of antipsychotic drugs in schizophrenia. Eur Psychiatry 11: 127-134. doi: 10.1016/0924-9338(96)85177-7
92. Lieberman JA. 1993. Prediction of outcome in first-episode schizophrenia. J Clin Psychiatry 54 Suppl: 13-17.
93. Lieberman JA, Bymaster FP, Meltzer HY, et al. 2008. Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev 60: 358-403. doi: 10.1124/pr.107.00107
94. Lincoln TM, Wilhelm K, Nestoriuc Y. 2007. Effectiveness of psychoeducation for relapse, symptoms, knowledge, adherence and functioning in psychotic disorders: a meta-analysis. Schizophr Res 96: 232-245.
95. Linszen DH, Dingemans PMAJ, Scholte WF, Lenior ME, Goldstein M. 1998. Early recognition, intensive intervention and other protective and risk factors for psychotic relapse in patients with first psychotic episodes in schizophrenia. Int Clin Psychopharmacol 13(suppl 1): s7-12.
96. Llorca PM, Abbar M, Courtet P, Guillaume S, Lancrenon S, Samalin L. 2013. Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness. BMC Psychiatry 13: 340. doi: 10.1186/1471-244X-13-340
97. Marder SR, Essock SM, Miller AL, et al. 2004. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 161: 1334-1349.
98. Markowitz M, Fu DJ, Levitan B, Gopal S, Turkoz I, Alphs L. 2013. Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies. Ann Gen Psychiatry 12: 22. doi: 10.1186/1744-859X-12-22
99. Masand PS, Roca M, Turner MS, Kane JM. 2009. Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review. Prim Care Companion J Clin Psychiatry 11: 147-154. doi: 10.4088/PCC.08r00612
100. McCreadie RG, Dingwall JM, Wiles DH, Heykants JJ. 1980. Intermittent pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia. Br J Psychiatry 137: 510-517.
101. McCreadie R, Mackie M, Morrison D, Kidd J. 1982. Once weekly pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia. Br J Psychiatry 140: 280-286.
102. McGlashan TH. 1988. A selective review of recent North American long-term followup studies of schizophrenia. Schizophr Bull 14: 515-542.
103. Miclutia I, Junjan V, Popescu CA, Tigan S. 2007. Migration, mental health and costs consequences in Romania. J Ment Health Policy Econ 10: 43-50.
104. Miklowitz DJ. 1994. Family risk indicators in schizophrenia. Schizophr Bull 20: 137-149.
105. Miller BJ, Bodenheimer C, Crittenden K. 2011. Second-generation antipsychotic discontinuation in first episode psychosis: an updated review. Clin Psychopharmacol Neurosci 9: 45-53. doi: 10.9758/cpn.2011.9.2.45
106. Mino Y, Shimodera S, Inoue S, Fujita H, Fukuzawa K. 2007. Medical cost analysis of family psychoeducation for schizophrenia. Psychiatry Clin Neurosci 61: 20-24.
107. Mizuno Y, Bies RR, Remington G, et al. 2012. Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: a cross-sectional study. Prog Neuropsychopharmacol Biol Psychiatry 37: 182-187. doi: 10.1016/j.pnpbp.2011.12.013
108. Moilanen J, Haapea M, Miettunen J, et al. 2013. Characteristics of subjects with schizophrenia spectrum disorder with and without antipsychotic medication - a 10-year follow-up of the Northern Finland 1966 Birth Cohort study. Eur Psychiatry 28: 53-58. doi: 10.1016/j.eurpsy.2011.06.009
109. Molina V, Sanz J, Sarramea F, Benito C, Palomo T. 2004. Lower prefrontal gray matter volume in schizophrenia in chronic but not in first episode schizophrenia patients. Psychiatry Res 131: 45-56.
110. Möller HJ. 2004. Course and long-term treatment of schizophrenic psychoses. Pharmacopsychiatry 37(Suppl 2): 126-135.
111. Moriguchi S, Bies RR, Remington G, et al. 2013. Estimated Dopamine D2 Receptor Occupancy and Remission in Schizophrenia: Analysis of the CATIE Data. J Clin Psychopharmacol 33: 682-685. doi: 10.1097/JCP.0b013e3182979a0a
112. Motlova L, Dragomirecka E, Spaniel F, et al. 2006. Relapse prevention in schizophrenia: Does group family psychoeducation matter? One-year prospective follow-up field study. Int J Psychiatry Clin Pract 10: 38-44.
113. Müller N. 2004. Mechanisms of relapse prevention in schizophrenia. Pharmacopsychiatry 37(Suppl 2): S141-147.
114. Mwaba K, Molamu RB. 1998. Perceived causes of relapse among a sample of recovering psychiatric patients at a Mafikeng hospital. Curationis 21: 55-57.
115. Narasimhan M, Pae CU, Masand N, Masand P. 2007. Partial compliance with antipsychotics and its impact on patient outcomes. Int J Psychiatry Clin Pract 22: 102-111.
116. Nordon C, Rouillon F, Azorin JM, Barry C, Urbach M, Falissard B. 2013. Trajectories of antipsychotic response in drug-naive schizophrenia patients: results from the 6-month ESPASS follow-up study. Acta Psychiatr Scand. doi: 10.1111/acps.12135. [Epub ahead of print]
117. Nuechterlein KH, Dawson ME, Ventura J, et al. 1994. The vulnerability/stress model of schizophrenic relapse: a longitudinal study. Acta Psychiatr Scand Suppl 382: 58-64.
118. Ohmori T, Ito K, Abekawa T, Koyama T. 1999. Psychotic relapse and maintenance therapy in paranoid schizophrenia: a 15 year follow up. Eur Arch Psychiatry Clin Neurosci 249: 73-78.
119. Olivares JM, Sermon J, Hemels M, Schreiner A. 2013. Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review. Ann Gen Psychiatry 12(1): 32. [Epub ahead of print]
120. Peluso MJ, Lewis SW, Barnes TR, Jones PB. 2012. Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs. Br J Psychiatry 200: 387-392. doi: 10.1192/bjp.bp.111.101485
121. Penttilä M, Jääskeläinen E, Haapea M, et al. 2010. Association between duration of untreated psychosis and brain morphology in schizophrenia within the Northern Finland 1966 Birth Cohort. Schizophr Res 123: 145-152. doi: 10.1016/j.schres.2010.08.016
122. Pharoah F, Mari J, Rathbone J, Wong W. 2010. Family intervention for schizophrenia. Cochrane Database Syst Rev Dec 8; (12): CD000088. doi: 10.1002/14651858.CD000088.pub2
123. Rathod S, Turkington D. 2005. Cognitive-behaviour therapy for schizophrenia: a review. Curr Opin Psychiatry 18: 159-163.
124. Remington G, Kwon J, Collins A, Laporte D, Mann S, Christensen B. 2007. The use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in outpatients with schizophrenia. Schizophr Res 90: 229-237.
125. Remington G, Seeman P, Feingold A, Mann S, Shammi C, Kapur S. 2011. "Extended" antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry 72: 1042-1048. doi: 10.4088/JCP.09m05866yel
126. Remington G, Foussias G, Agid O, Fervaha G, Takeuchi H, Hahn M. 2013. The neurobiology of relapse in schizophrenia. Schizophr Res. pii: S0920-9964(13)00554-9. doi: 10.1016/j.schres.2013.10.009. [Epub ahead of print]
127. Robinson D, Woerner MG, Alvir JM, et al. 1999. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 56: 241-247.
128. Roseliza-Murni A, Oei TP, Fatimah Y, Asmawati D. 2014. Schizophrenia relapse in Kuala Lumpur, Malaysia: do relatives' expressed emotion and personality traits matter? Compr Psychiatry 55: 188-198. doi: 10.1016/j.comppsych.2012.12.026
129. Rosenheck RA, Krystal JH, Lew R, et al. 2011. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med 364: 842-851. doi: 10.1056/NEJMoa1005987
130. Ruhrmann S, Schultze-Lutter F, Klosterkötter J. 2009. Intervention in the at-risk state to prevent transition to psychosis. Curr Opin Psychiatry 22: 177-183. doi: 10.1097/YCO.0b013e328324b687
131. Sampson S, Mansour M, Maayan N, Soares-Weiser K, Adams CE. 2013. Intermittent drug techniques for schizophrenia. Cochrane Database Syst Rev 7: CD006196. doi: 10.1002/14651858.CD006196.pub2
132. Schennach R, Obermeier M, Meyer S, et al. 2012. Predictors of relapse in the year after hospital discharge among patients with schizophrenia. Psychiatr Serv 63: 87-90. doi: 10.1176/appi.ps.201100084
133. Schennach-Wolff R, Jäger M, Mayr A, et al. 2011. Predictors of response and remission in the acute treatment of first-episode schizophrenia patients - is it all about early response? Eur Neuropsychopharmacol 21: 370-378. doi: 10.1016/j.euroneuro.2010.10.003
134. Schooler NR. 2006. Relapse prevention and recovery in the treatment of schizophrenia. J Clin Psychiatry 67(Suppl 5): 19-23.
135. Sheitman BB, Lieberman JA. 1998. The natural history and pathophysiology of treatment resistant schizophrenia. J Psychiatr Res 3: 143-150.
136. Soyka M. 1996. Dual Diagnosis in Patients with Schizophrenia: Issues in Pharmacological Treatment. CNS Drugs 5: 414-425.
137. Španiel F, Hrdlička J, Novák T, et al. 2012. Effectiveness of the information technology-aided program of relapse prevention in schizophrenia (ITAREPS): a randomized, controlled, double-blind study. J Psychiatr Pract 18: 269-280. doi: 10.1097/01.pra.0000416017.45591.c1
138. Stephens JH. 1978. Long-term prognosis and followup in schizophrenia. Schizophr Bull 4: 25-47.
139. Suzuki T. 2011. Which rating scales are regarded as 'the standard' in clinical trials for schizophrenia? A critical review. Psychopharmacol Bull 44: 18-31.
140. Suzuki T, Uchida H, Takeuchi H, et al. 2005. Simplifying psychotropic medication regimen into a single night dosage and reducing the dose for patients with chronic schizophrenia. Psychopharmacology (Berl) 181: 566-575.
141. Suzuki T, Uchida H, Nomura K, et al. 2008. Novel rating scales for schizophrenia - Targeted Inventory on Problems in Schizophrenia (TIP-Sz) and Functional Assessment for Comprehensive Treatment of Schizophrenia (FACT-Sz). Schizophr Res 106: 328-336. doi: 10.1016/j.schres.2008.08.013
142. Suzuki T, Uchida H, Watanabe K, Kashima H. 2011. Factors associated with response to clozapine in schizophrenia: a review. Psychopharmacol Bull 44: 32-60.
143. Suzuki T, Remington G, Mulsant BH, et al. 2012. Defining treatment-resistant schizophrenia and response to antipsychotics: a review and recommendation. Psychiatry Res 197: 1-6. doi: 10.1016/j.psychres.2012.02.013
144. Takeuchi H, Suzuki T, Uchida H, Watanabe K, Mimura M. 2012. Antipsychotic treatment for schizophrenia in the maintenance phase: a systematic review of the guidelines and algorithms. Schizophr Res 134: 219-225. doi: 10.1016/j.schres.2011.11.021
145. Takeuchi H, Suzuki T, Remington G, et al. 2013. Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study. Schizophr Bull 39: 993-998. doi: 10.1093/schbul/sbt090
146. Takeuchi H, Fervaha G, Uchida H, Suzuki T, Bies RR, Grönte D, Remington G. 2014. Impact of once- versus twice-daily perphenazine dosing on clinical outcomes: an analysis of the CATIE data. J Clin Psychiatry 75: 506-511. doi: 10.4088/JCP.13m08695
147. Tauscher-Wisniewski S, Kapur S, Tauscher J, et al. 2002. Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade. J Clin Psychiatry 63: 992-997.
148. Taylor M, Chaudhry I, Cross M, et al. 2005. Towards consensus in the long-term management of relapse prevention in schizophrenia. Hum Psychopharmacol 20: 175-181.
149. Thompson PM, Bartzokis G, Hayashi KM, et al. 2009. Time-lapse mapping of cortical changes in schizophrenia with different treatments. Cereb Cortex 19: 1107-1123. doi: 10.1093/cercor/bhn152
150. Tiihonen J, Wahlbeck K, Lönnqvist J, et al. 2006. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 333(7561): 224.
151. Tiihonen J, Lönnqvist J, Wahlbeck K, et al. 2009. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 374(9690): 620-627. doi: 10.1016/S0140-6736(09)60742-X
152. Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. 2011. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 168: 603-609. doi: 10.1176/appi.ajp.2011.10081224
153. Tollefson GD, Andersen SW, Tran PV. 1999. The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone. Biol Psychiatry 46: 365-373. doi: 10.1016/j.schres.2013.08.001
154. Trevino K, McClintock SM, Husain MM. 2010. A review of continuation electroconvulsive therapy: application, safety, and efficacy. J ECT 26: 186-195. doi: 10.1097/YCT.0b013e3181efa1b2
155. Trollor JN, Chen X, Chitty K, Sachdev PS. 2012. Comparison of neuroleptic malignant syndrome induced by first- and second-generation antipsychotics. Br J Psychiatry 201: 52-56. doi: 10.1192/bjp.bp.111.105189
156. Uchida H, Suzuki T, Takeuchi H, Arenovich T, Mamo DC. 2011a. Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis. Schizophr Bull 37: 788-799. doi: 10.1093/schbul/sbp149
157. Uchida H, Takeuchi H, Graff-Guerrero A, Suzuki T, Watanabe K, Mamo DC. 2011b. Predicting dopamine D receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysis. J Clin Psychopharmacol 31: 318-325. doi: 10.1097/JCP.0b013e318218d339
158. Uchida H, Takeuchi H, Graff-Guerrero A, Suzuki T, Watanabe K, Mamo DC. 2011c. Dopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysis. J Clin Psychopharmacol 31: 497-502. doi: 10.1097/JCP.0b013e3182214aad
159. Ulrich S, Baumann B, Wolf R, et al. 2003. Therapeutic drug monitoring of clozapine and relapse - a retrospective study of routine clinical data. Int J Clin Pharmacol Ther 41: 3-13.
160. Ventura J, Subotnik KL, Guzik LH, et al. 2011. Remission and recovery during the first outpatient year of the early course of schizophrenia. Schizophr Res 132: 18-23. doi: 10.1016/j.schres.2011.06.025
161. Weiser M, Davidson M, Noy S. 2005. Comments on risk for schizophrenia. Schizophr Res 2005; 79: 15-21.
162. Wiersma D, Nienhuis FJ, Slooff CJ, Giel R. 1998. Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort. Schizophr Bull 24: 75-85.
163. Witticke D, Seidling HM, Klimm HD, Haefeli WE. 2012. Do we prescribe what patients prefer? Pilot study to assess patient preferences for medication regimen characteristics. Patient Prefer Adherence 6: 679-684. doi: 10.2147/PPA.S35950
164. Wunderink L, Nienhuis FJ, Sytema S, Slooff CJ, Knegtering R, Wiersma D. 2007. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. J Clin Psychiatry 68: 654-661.
165. Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ. 2013. Recovery in Remitted First-Episode Psychosis at 7 Years of Follow-up of an Early Dose Reduction/Discontinuation or Maintenance Treatment Strategy: Long-term Follow-up of a 2-Year Randomized Clinical Trial. JAMA Psychiatry 70: 913-920. doi: 10.1001/jamapsychiatry.2013.19
166. Xiang YQ, Zhang ZJ, Weng YZ, et al. 2006. Serum concentrations of clozapine and norclozapine in the prediction of relapse of patients with schizophrenia. Schizophr Res 83: 201-210.
167. Xiang YT, Wang CY, Weng YZ, et al. 2011. Predictors of relapse in Chinese schizophrenia patients: a prospective, multi-center study. Soc Psychiatry Psychiatr Epidemiol 46: 1325-1330. doi: 10.1007/s00127-010-0304-1
168. Xie H, McHugo GJ, Fox MB, Drake RE. 2005. Substance abuse relapse in a ten-year prospective follow-up of clients with mental and substance use disorders. Psychiatr Serv 56: 1282-1287.
169. Yoshida K, Suzuki T, Uchida H, Mimura M. 2013. Absence of evidence that the pro re nata regimen confers benefit: a review of the studies. Int Clin Psychopharmacol 28: 228-237. doi: 10.1097/YIC.0b013e328362db99
170. Zipursky RB, Reilly TJ, Murray RM. 2013. The Myth of Schizophrenia as a Progressive Brain Disease. Schizophr Bull 39: 1363-1372. doi: 10.1093/schbul/sbs135
171. Zipursky RB, Menezes NM, Streiner DL. 2014. Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review. Schizophr Res 152: 408-414. doi: 10.1016/j.schres.2013.08.001